OBIO vs PLUR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
OBIO Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while PLUR counters with relative strength in Valuation. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus PLUR at 3.6x Forward P/E and -2454.5% operating margin (-15.8% YoY). In options structure, OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro) against PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | PLUR Revenue | OBIO Op. Margin | PLUR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -67462.0% | PLUR |
| FY2019 | N/A | $0M | N/A | -65800.0% | PLUR |
| FY2020 | N/A | $0M | N/A | -128156.5% | PLUR |
| FY2022 | $0M | $0M | -924.3% | -17774.8% | OBIO |
| FY2023 | $0M | $0M | -1866.2% | -9493.4% | OBIO |
| FY2024 | $0M | $0M | -2437.5% | -6796.9% | OBIO |
| FY2025 | $30M | $0M | -154.7% | -1659.9% | OBIO |
| FY2026 | N/A | $0M | N/A | -2454.5% | PLUR |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OBIO | PLUR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $570.6M | $15.1M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | 3.6x | Lower Multiple | PLUR |
| Forward P/E Ratio Valuation | N/M | 3.6x | Lower Multiple | PLUR |
| Revenue Growth (YoY) Growth | -89.4% | -15.8% | Higher Growth | PLUR |
| Operating Margin (TTM) Profitability | -195.4% | -2454.5% | Higher Margin | OBIO |
| Net Profit Margin Profitability | -182.5% | 0.0% | Higher Margin | PLUR |
| Return on Equity (ROE) Capital Efficiency | -182.3% | -1022.0% | Higher ROE | OBIO |
| 52-Week Range Position Momentum | 89% ($3โ$7) | 2% ($1โ$5) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | 1.15ฮฒ ยท 80% Vol | 0.80ฮฒ ยท 102% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 28.8 / 100 (SELL) | Higher Composite | OBIO |